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Summary
Conclusions. Adaptive changes in exocrine and endocrine pancreatic function, as well as changes
in pancreas size and morphology, were not observed after 4 wk of oral pancreatic enzyme application.
These findings suggest that the normal pancreas does not significantly adapt—either morphologically
or functionally—to a 4-wk oral application of high-dose pancreatic enzymes.
Background. The control of exocrine pancreatic enzyme secretion is not completely understood. Although
it has been established that exocrine pancreatic secretion is mainly regulated in the short-term by the amount
of pancreatic enzymes in the proximal small intestine, it is not known whether long-term application of
pancreatic enzymes causes changes in exocrine pancreatic secretion in humans.
Methods. Twelve healthy male volunteers (median age 27 yr) participated in a prospective, randomized,
placebo-controlled, double-blind study. Six were placed in the treatment group and six in the placebo group.
Over a 4-wk period, the six subjects in the treatment group took 18 capsules of Panzytrat (20,000 units of
lipase, 18,000 units of amylase, and 1000 units of protease per capsule) daily. Before (wk 0), 4 wk following
pancreatic enzyme application and 2 wk afterward, a secretin-cerulein test was carried out in all subjects to
study exocrine pancreatic function (trypsin, chymotrypsin, bicarbonate content, and total pancreatic fluid
secretion in the duodenum). One day following the secretin-cerulein test, a standard test meal was given to
all subjects to analyze endocrine pancreatic function. Additionally, before starting the treatment, once per
week during treatment and 2 wk afterward, an ultrasound examination of the pancreas was carried out to see
whether there was any change in pancreas size and morphology.
Results. Trypsin content in the duodenal aspirates following simultaneous stimulation with secretin and
cerulein after 4 wk of high-dose pancreatic enzyme application was 92% in the treatment group and 82% in
the placebo group compared with the wk 0 test results (100%). Two weeks after enzyme application, the
secretin/cerulein-stimulated trypsin content was 88% in the treatment group and 107% in the placebo group.
None of these changes was statistically significant. The same results were seen for chymotrypsin content,
amylase, and bicarbonate content as well as for total pancreatic fluid secretion. Additionally, no change in
the endocrine pancreatic function could be observed after 4 wk of pancreatic enzyme treatment. Pancreas
ultrasonography revealed no alteration in pancreas size or parenchymal structure during the 4 wk of treatment
and the following 2 wk.
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Introduction
The exocrine pancreas secretes an alkaline enzyme-
rich fluid, which is needed to effect the major diges-
tive activity of the gastrointestinal tract. From several
studies we have learned that exocrine pancreatic
secretion is under both hormonal and neural control:
Cholecystokinin, an intestinal hormone, evokes an
enzyme-rich secretion from the pancreas, and the
vagus nerve, as a part of the parasympathetic ner-
vous system, also exerts some control over pancre-
atic secretion (1–6).
Although it has been well established from stud-
ies in animals (7–13) that the presence of pancreatic
enzymes (trypsin, chymotrypsin) in the proximal
small intestine causes a negative feedback regula-
tion on pancreatic enzyme secretion, the findings in
humans remain controversial. Though most studies
demonstrate a negative feedback control of pancre-
atic enzyme secretion regulated by trypsin (14–18)
and mediated by the release of the intestinal hor-
mone cholecystokinin (1), other studies conversely
report that inhibition of intestinal trypsin does not
stimulate exocrine pancreatic secretion (19,20).
However, most of these studies focus on short-term
effects of the feedback regulation, and little is known
about long-term feedback mechanisms and adaptive
changes of exocrine and endocrine pancreatic secre-
tion in humans.
In a subgroup of patients with chronic pancreati-
tis and mild-to-moderate exocrine pancreatic
insufficiency, it could be demonstrated that oral
pancreatic enzyme application decreases abdominal
pain (21–27). These observations seem to fit with
data in humans that demonstrate a negative feed-
back regulation for pancreatic exocrine secretion
controlled by the amount of trypsin in the upper
small intestine. However, these reports were only
clinical observations in a selected number of patients
with chronic pancreatitis.
Under the assumption that, in humans, a negative
feedback mechanism exists, which is controlled by
the content of pancreatic enzymes in the upper small
bowel, high-dose pancreatic enzyme application
during eating should diminish food-induced pancre-
atic enzyme secretion. This expected downregula-
tion of pancreatic enzyme secretion could lead to a
decrease in pancreatic enzyme synthesis and thereby
to a functional adaptation of pancreatic parenchyma.
Therefore, the aim of our prospective, random-
ized, placebo-controlled, double-blind study was to
investigate the effects of a 4-wk high-dose pancre-
atic enzyme application on exocrine and endocrine
pancreatic function, as well as on the pancreas size
and morphology in humans.
Methods
Subjects
Twelve healthy male volunteers (medical stu-
dents), 23–33 yr old (median age 27 yr), participated
in this study. All subjects were within ± 10% of their
ideal body wt, none were taking medication, and
none had any history of previous pancreatic or
nonpancreatic gastrointestinal disease. The subjects
were randomly assigned to the treatment or the pla-
cebo group in a double-blind fashion in the order in
which written informed consent was given. The
study protocol was approved by the University ethi-
cal committee.
Medication
Panzytrat (Nordmark, Uetersen, Germany) is an
acid-resistant microcapsule containing pig pancre-
atin, which consists of 20,000 units triacylglycerol-
lipase, 18,000 units amylase, and 1000 units
protease. The placebo capsules were identical to the
panzytrat medication, except that no pancreatic
enzymes were added to the vehicle.
Procedures
According to the study design (prospective, ran-
domized, placebo-controlled, double-blind), the sub-
jects took 18 oral capsules of either Panzytrat or the
placebo daily over a 4-wk period. During the study,
the subjects ate breakfast and lunch with six capsules
of Panzytrat (one capsule 10 min before the meal,
four capsules during the meal, and one capsule 10 min
after the meal), and they ate dinner and one between-
meal snack with three capsules of Panzytrat (one
capsule 10 min before, one capsule during, and one
capsule 10 min after the meal) daily. Before the study
(wk 0), at the end of 4 wk of pancreatic enzyme
application (wk 4), and 2 wk after the end of the
pancreatic enzyme substitution (wk 6), a secretin-
cerulein test was carried out in all subjects to mea-
sure the exocrine pancreatic secretion (amylase,
trypsin, chymotrypsin, bicarbonate, and total pan-
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creatic fluid volume). At the same time, blood
samples were obtained to measure amylase and
lipase serum activity.
In addition, 1 d following the secretin-cerulein
test, a standard test meal was given to analyze
changes in the secretion of the pancreatic islet hor-
mones insulin and glucagon as well as to measure
changes in the blood glucose levels.
Before pancreatic enzyme treatment, once each
week during treatment, and once per week in the first
2 wk after treatment, an ultrasound examination of
the pancreas was carried out to see whether there was
any change in the size and structure of the pancreas.
Furthermore, during the period of study medication,
the volunteers completed a questionnaire to ensure
that the study medication was taken regularly and
according to the study protocol.
Additionally, the daily calorie intake as well as
the body weight of each subject was registered dur-
ing the test period using an alimentation diary to
ensure no excess calorie intake.
Secretin-Cerulein Test
At study wk 0, 4, and 6, duodenal aspirates were
sampled with a double-lumen catheter, which was
placed in the duodenum under X-ray control, with its
tip at the papilla Vateri and the second opening in
the stomach.
The test started with duodenal aspiration in 10-min
intervals for 30 min during the baseline phase. Aspi-
ration in 10-min intervals was performed for 60 min
after bolus injection of secretin (1 U/kg) and for
60 min during continuous infusion of secretin
(1 U/kg/h) and cerulein (80 ng/kg/h). Duodenal
aspirates were collected on ice and assayed imme-
diately for trypsin, chymotrypsin, amylase, bicarbon-
ate, and total volume. During the secretin-cerulein
test, blood samples were obtained at 15, 30, 60, 90,
120, and 150 min to measure serum amylase and
lipase activity.
Standard Test Meal
After an overnight fast of 10 h, all subjects were
given a liquid standard test meal 1 d after the secre-
tin-cerulein test (study wk 0, 4, and 6). The test meal
consisted of 500 mL H2O, 5 mL thistle oil, and 130 g
(2126 kJ) Meriten (Sandoz-Wander AG, Bern, Swit-
zerland) containing 73.3 g carbohydrate, 39.6 g pro-
tein, and 5.72 g fat. One minute before the test meal
and 1, 3, 5, 10, 15, 30, 45, 60, 75, 90, 120, 150, and
180 min afterward, blood samples were taken and
mixed with an EDTA-trasylol solution (Bayer AG,
Leverkusen, Germany; 750 mg EDTA in 50 mL
aprotinin, ratio 1:10). The blood sugar and the islet
cell hormones insulin and glucagon were measured
in these plasma samples.
Ultrasonography
In wk 0, 1, 2, 3, 4, 5, and 6 of the study, an ultra-
sonography of the pancreas was performed, with
special attention paid to the size and structure of the
pancreas. The sizes of the head (oblique and vertical
diameter), the body (vertical diameter), and the tail
(vertical diameter) of the pancreas were measured as
well as the size of the main pancreatic duct if
visualizable.
Pancreatic Enzyme Analysis
of the Duodenal Aspirates
Trypsin was measured by the hydrolysis of tosyl-
L-arginin methylester, chymotrypsin by the hydroly-
sis of n-benzoyl-L-tyrosinester, amylase by reduction
of 3.5-dinitro-salicylic acid, and bicarbonate by a
titrimetric method, as previously reported (28–30).
Blood Glucose, Serum Amylase,
and Lipase Measurement
The blood glucose concentration was measured
by the glucose dehydrogenase method (Granutest,
Merck, Darmstadt, Germany) in an automatic ana-
lyzer (Eppendorf, Hamburg, Germany). Serum amy-
lase and lipase were measured by hydrolysis of
3p-nitrophenylmaltoheptasoid and triolin, respec-
tively, in an automatic analyzer (Boehringer Mann-
heim, Mannheim, Germany).
Hormone Analysis
Plasma insulin concentration was measured with
the commercial insulin radioimmunoassay kit
SB-INSI-I (Sorin Biomedic, Italy). The sensitivity
was 0.082 ng/mL, the interassay variance was 2.8%,
and the intra-assay variance was 8.6%.
The glucagon serum plasma concentration was
measured with a radioimmunoassay using the
glucagon antiserum K30 (kind gift of Roger Unger,
University of Texas, Dallas, TX) and Indium
125-labeled glucagon. The interassay variance and
the intraassay variance of the glucagon radioimmuno-
assay were 14 and 9%, respectively.
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Statistical Analysis
The results are expressed as mean ± standard error
of mean (SEM). For statistical analysis, the Student
t-test was used. Significance was defined as p < 0.05.
Results
Comparison of Groups
The subjects were randomly distributed between
the treatment and placebo groups. The groups were
comparable with regard to subjects’ age, gender,
body weight, and daily calorie intake, and there was
no change in the subjects’ body weight and daily
calorie intake during the 4 wk of pancreatic enzyme
application and 2 wk afterward.
No statistically significant difference could be
detected in any test carried out before enzyme medi-
cation was started (wk 0).
Side Effects
There were weekly assessments of serum sodium,
potassium, ALT, AST, GGT, PT, PTT, creatinine, and
BUN in all subjects. Before, during, and 2 wk after
the test period, no subject showed any abnormality.
None of the subjects suffered from severe side
effects. Two subjects in the treatment group
complained of mild nausea, epigastric pain, and
heartburn. These symptoms disappeared spontane-
ously, and none led to termination of participa-
tion in the study.
Exocrine Pancreas Secretion
All test results were compared with the test results
obtained before the pancreatic enzyme application
was started (wk 0). At wk 0, all subjects had normal
exocrine pancreatic function as determined by the
secretin-cerulein test.
Trypsin
Following bolus stimulation with secretin (1 U/kg),
the duodenal trypsin content after 4 wk of high-dose
enzyme application was 83% in the treatment and
73% in the placebo group, compared with the wk 0
test results (100%). Two weeks after the end of high-
dose enzyme application, the duodenal trypsin con-
tent following secretin stimulation was 87% in the
treatment group and 79% in the placebo group, com-
pared with the wk 0 test results. The trypsin content
following continuous simultaneous stimulation with
secretin and cerulein was 92% in the treatment group
and 82% in the placebo group after 4 wk of high-dose
enzyme application (Fig. 1). Two weeks after the
end of high-dose enzyme application, the duodenal
trypsin content following continuous simultaneous
stimulation with secretin and cerulein was 88% in
the treatment group and 107% in the placebo group,
compared with the wk 0 test results (Fig. 1). None of
these changes in the trypsin content—neither
between the different tests at wk 0, 4, and 6, nor
between the treatment and placebo groups—was sta-
tistically significant.
Fig. 1. Exocrine pancreatic function analyzed with the
secretin-cerulein test before pancreatic enzyme applica-
tion (wk 0), following 4 wk of pancreatic enzyme appli-
cation (wk 4), and 2 wk after the end of pancreatic enzyme
application (wk 6). Cumulative pancreatic secretion of
trypsin (A) and chymotrypsin (B) after continuous infu-
sion of secretin (1 U/kg/h) and cerulein (80 ng/kg/h) in the
placebo and treatment groups. Values are mean ± SEM.
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Chymotrypsin
Chymotrypsin showed a pattern comparable to
that of trypsin. There were no statistically signifi-
cant changes in the chymotrypsin content at the differ-
ent test dates between the treatment and the placebo
groups: The chymotrypsin content after stimulation
with secretin was 59% (treatment group) and 71% (pla-
cebo group) after 4 wk of high-dose enzyme application
and 54% (treatment) and 63% (placebo) 2 wk after the
end of high-dose enzyme application. Following con-
tinuous simultaneous stimulation with secretin-cerulein,
the chymotrypsin content was 78% (treatment) and
85% (placebo) after 4 wk of high-dose enzyme applica-
tion and 68% (treatment) and 78% (placebo) 2 wk
after the end of enzyme application (wk 6) (Fig. 1).
Amylase
Following stimulation with secretin, the duode-
nal amylase content at wk 4 was 86% in the treatment
group and 77% in the placebo group and at wk 6 was
77% in the treatment group and 70% in the placebo
group, compared with the results before enzyme
application at wk 0. Following continuous stimula-
tion with secretin and cerulein, the duodenal amy-
lase content at wk 4 was 107% in the treatment group
and 91% in the placebo group. At wk 6, 2 wk after the
end of enzyme application, duodenal amylase con-
tent was 102% in the treatment group and 106% in
the placebo group. Again, none of these changes was
statistically significant.
Bicarbonate
The duodenal bicarbonate content following
stimulation with secretin was 94% (treatment) and
104% (placebo) at wk 4 and 76% (treatment) and
93% (placebo) at wk 6. Duodenal bicarbonate con-
tent following continuous stimulation with secretin
and cerulein was 81% (treatment) and 109% (placebo)
at wk 4 and 93% (treatment) and 108% (placebo) at
wk 6 (Fig. 2). None of these changes in the duodenal
bicarbonate content was statistically significant.
Total Pancreatic Volume Secretion
The total pancreatic juice vol secretion after bolus
stimulation with secretin was 94% (treatment) and
103% (placebo) at wk 4 and 84% (treatment) and
101% (placebo) at wk 6. After simultaneous stimu-
lation with secretin and cerulein, the total secretion
was 97% (treatment) and 104% (placebo) at wk 4
and 90% (treatment) and 100% (placebo) at wk six
(Fig. 2). None of the changes was significant.
Serum Lipase and Amylase
Lipase and amylase activity in the serum before
and after the secretin test and after the secretin-
cerulein stimulation at 0, 4, and 6 wk showed no
statistically significant difference, either between the
treatment and placebo groups or among the results at
0, 4, and 6 wk.
Endocrine Pancreatic Secretion
Insulin
Plasma insulin levels showed a peak 30 min after
application of the standard test meal and had decreased
Fig. 2. Exocrine pancreatic function analyzed with the
secretin-cerulein test before pancreatic enzyme applica-
tion (wk 0), following 4 wk of pancreatic enzyme appli-
cation (wk 4), and 2 wk after the end of the pancreatic
enzyme application (wk 6). Cumulative pancreatic total
volume fluid secretion (A) and bicarbonate secretion (B)
after bolus application of secretin (1 U/kg) in the placebo
and treatment groups. Values are mean ± SEM.
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to the baseline concentration by around 180 min.
There were no statistically significant differences,
either between the treatment and placebo groups or
among the test meals at 0, 4, and 6 wk (Fig. 3).
Glucagon
Following application of the standard test meal,
plasma glucagon levels increased during the first
10 min and remained constant afterward. No sig-
nificant changes could be observed between the
treatment and placebo groups at wk 0, 4, and 6
(Fig. 4).
Blood Glucose
There were no statistically significant changes in
the physiologic response of the blood glucose levels
to the test meals between the treatment and placebo
groups at the different test times.
Ultrasonography of the Pancreas
There was no significant increase or decrease in
the size of the head, the body, or the tail of the pan-
creas, nor any observable change in the structure of
the pancreas, when the treatment and placebo groups
were compared before, during, and 2 wk after the
pancreatic enzyme application.
Discussion
A number of in vivo and in vitro studies in animals
demonstrate a negative feedback regulation of the
exocrine pancreas secretion by pancreatic enzymes in
the upper small intestine (7–13,31–33). Several stud-
ies have found a feedback inhibition of pancreatic
secretion in man, regulated by trypsin (14–18,34–36)
and mediated by cholecystokinin (1,37). However,
Fig. 3. Endocrine pancreatic function analyzed by
application of a standard test meal. Baseline and post-
prandial insulin levels before pancreatic enzyme applica-
tion (wk 0) (A) and following 4 wk of pancreatic enzyme
application (wk 4) (B) in the placebo and treatment
groups. Values are mean ± SEM.
Fig. 4. Endocrine pancreatic function analyzed by
application of a standard test meal. Baseline and post-
prandial glucagon levels before pancreatic enzyme appli-
cation (wk 0) (A) and following 4 wk of pancreatic
enzyme application (wk 4) (B) in the placebo and treat-
ment groups. Values are mean ± SEM.
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other studies have failed to demonstrate a stimulation
of pancreatic secretion by inhibition of trypsin (19,20),
as would be expected with this model.
In this study, we demonstrated that exocrine pan-
creatic secretion, stimulated by secretin and chole-
cystokinin, was not altered by oral application of
high dosages of pancreatic enzymes. Moreover, there
was no inhibition of the bicarbonate secretion and
the total volume of pancreatic secretion. Also, there
was no change in the lipase and amylase activity in
the serum. However, other studies—focusing on
short-term effects—provide strong support for the
theory that feedback regulation of pancreatic enzyme
secretion operates in man (14,15). Owyang et al. (14)
demonstrated in a dose response study of 12 healthy
individuals that the minimal concentration of trypsin
in the duodenum required to inhibit pancreatic
secretion was 0.5 g/L, and that maximal suppression
was observed with 1 g/L. The suppression seemed to
be enzyme-specific, since suppression was not
observed with intraduodenal perfusion of lipase or
amylase. Furthermore, double-blind trials have dem-
onstrated that pancreatic enzyme application may
decrease the abdominal pain in selected patients with
chronic pancreatitis (21–27,38). Slaff et al. (26)
could show that oral pancreatic extract administra-
tion decreased abdominal pain in chronic pancreati-
tis patients, and that intraduodenal perfusion with
proteases suppressed exocrine secretion in those
patients. Additionally, they were able to demonstrate
a significant decrease in basal and stimulated chy-
motrypsin output after 30 d of oral pancreatic extract
treatment. However, these results were obtained only
in a small subgroup of three patients with chronic pan-
creatitis. These clinical observations seem to fit in with
other studies in man that demonstrate a negative feed-
back regulation for pancreatic enzyme secretion con-
trolled by the concentration of trypsin in the upper small
intestine. Liener et al. (18) could clearly show such a
negative feedback control of exocrine pancreatic secre-
tion. Administration of a trypsin/chymotrypsin inhibi-
tor (Bowman-Birk) significantly increased pancreatic
output and concentration of trypsin, chymotrypsin,
elastase, and amylase, indicating that the human
pancreas is responsive to intraduodenally adminis-
tered protease inhibitors. However, such short-term
experiments do not reveal the physiologic conse-
quences that might accompany long-term protease
inhibitor or pancreatic enzyme ingestion.
The hypothesis of our study was that with high
doses of oral pancreatic enzyme application, endo-
genous pancreatic enzyme secretion is reduced. We
hypothesized that the application of high-dose pan-
creatic enzymes during food uptake would abolish
or significantly reduce food-induced pancreatic
enzyme secretion and thereby down-regulate pan-
creatic enzyme synthesis in the acinar cells. This in
turn would lead to pancreatic atrophy and non-
adequate response to endogenous- or exogenous-
induced pancreatic enzyme secretion.
The following mechanisms may be responsible
for our failure to detect changes in pancreatic enzyme
secretion following the application of pancreatic
enzymes over 4 wk:
1. The concentration of enzymes given in the study
was too low to inhibit food-induced pancreatic
secretion.
2. The enzyme preparation used does not contain
trypsin. As mentioned above, there seems to be a
minimal trypsin concentration in the duodenum
necessary to exert inhibition of pancreatic enzyme
secretion, and the suppression seems to be enzyme-
specific. Trypsin inhibits pancreatic secretion,
whereas lipase and amylase do not (26).
3. The secretin and cholecystokinin analog used in
the secretin-cerulein test could have evoked a
maximal response of the exocrine pancreatic
secretion, thereby masking the inhibitory effect
of orally administered pancreatic enzymes on
pancreatic secretion.
4. Because only stimulated pancreatic secretion
was tested, no certain conclusion could be drawn
concerning the effect of high-dose pancreatic
enzyme application on interdigestive pancreatic
enzyme secretion.
In the present study, no statistically significant
difference could be detected in the endocrine pan-
creatic function, as determined with the application
of a standard test meal at three time points: before
high-dose pancreatic enzyme treatment, after 4 wk
of treatment, and 2 wk after the end of treatment. The
endocrine pancreas (islet cells) and the exocrine
pancreas are anatomically closely related, so that,
for example, inflammation may affect the endocrine
as well as the exocrine pancreas. However, the regu-
lation of exocrine pancreatic secretion seems to be
independent of endocrine pancreatic secretion, and
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much is known about the feedback mechanisms of
the various islet cell hormones. Thus it is not surpris-
ing that there have been no studies investigating the
regulatory effect of exocrine pancreatic enzymes on
endocrine pancreatic function. As expected, our
study could not demonstrate any significant changes
in the serum insulin, glucagon, or blood glucose
concentrations as a result of 4 wk of pancreatic
enzyme application.
In this study, we were able to demonstrate by
ultrasonography that pancreas size and parenchymal
structure are not altered during 4 wk of high-dose
pancreatic enzyme treatment. This might be a result
of limitations in the sensitivity of ultrasonography to
detect minor morphological changes in the pancreas.
However, only young, healthy volunteers were included
in our study, and the analysis of pancreatic morphology
by contrast-enhanced computed tomography was not
possible because of radiation exposure.
Lee et al. (39) found hypertrophic changes in the
rat pancreas in the presence of high-serum cholecys-
tokinin concentration. Similarly, Solomon et al.
(32,33) showed that chronic administration of exo-
genous cholecystokinin to rats has a marked trophic
effect on the pancreas; however, they conversely
reported that the administration of cerulein to dogs
for as long as 2 wk had no trophic effect on the pan-
creas. These findings indicate that adaptive changes
of the pancreas in response to exogenous hormone
application might be species-specific. The present
study in humans—the first to our knowledge—
showed no change in the size and morphology of the
pancreas during 4 wk of high-dose oral pancreatic
enzyme application and 2 wk afterward.
There are several possible explanations for this
result. First, it is possible that the human pancreas
does not adapt to exogenous enzyme application.
Second, perhaps we were not able to detect adaptive
pancreatic changes by ultrasonography. And third, it
could have been that the time schedule of enzyme
application and the dosage of enzymes were not suf-
ficient to induce changes in the size and morphology
of the human pancreas.
Most studies focus on the short-term effect of
pancreatic feedback regulation, whereas the study
presented here is the first that investigates the effects
of 4 wk of pancreatic enzyme application on pancre-
atic function in healthy volunteers. With our study
design, we could not detect morphological and func-
tional changes after 4 wk of oral pancreatic enzyme
application. No statistically significant effect on the
exocrine and endocrine pancreatic function or on the
pancreas size and structure were observed.
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